An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

In this episode, Adam Weiner, MD, and Michael Leapman, MD, discuss the current state of active surveillance for intermediate-risk prostate cancer. In this inaugural episode of The UroOnc Minute from ...

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025. Data from the KEYNOTE-905 trial (NCT03924895) showed that perioperative enfortumab vedotin ...

In this debut episode of The UroOnc Minute, host Adam Weiner, MD, a urologic oncologist and surgeon-scientist at Cedars-Sinai Medical Center, introduces listeners to a new Urology Times podcast ...

The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a finite treatment period of 52 weeks in patients with high-risk biochemically relapsed prostate cancer. In ...

Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

Panelists discuss how IsoPSA improves diagnostic accuracy by targeting PSA protein structure, offering clearer insights for patient selection than concentration-based testing. Panelists discuss how ...

Discover innovative approaches to treating premature ejaculation with insights from leading experts in sexual health and urology. At the 2025 Sexual Medicine Society of North America meeting in ...

Panelists discuss how structure-based biomarkers such as IsoPSA improve risk stratification by distinguishing aggressive disease from indolent cases more effectively than PSA level alone. Panelists ...

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer. 3. Terence Friedlander, MD, provides ...